BD9
Well-Known Member
DEA set to rule on rescheduling marijuana. No time line given
Article
The DEA has already received the Food and Drug Administration's recommendation on the rescheduling, which is a key part of the rescheduling process stipulated by the Controlled Substance Act, says Russell Baer, a special agent at the DEA's office of public affairs. Baer won't reveal what the recommendation was. The DEA will now conduct its own eight-factor analysis to study the drug's potential for abuse, the current state of medical and scientific knowledge, the history and pattern of abuse, and other considerations. Once that is complete, the DEA's administrator, Chuck Rosenberg, makes the final call.
Baer wouldn't give a specific date for the decision, but he said the process is nearly complete and the agency is waiting to hear Rosenberg's decision whether or not marijuana is considered a medicine or if it's still a dangerous substance.
While the DEA continues to deliberate on whether or not to reschedule cannabis, the agency will continue to support increased medical and scientific studies on weed, says Baer.
According to the DEA, the total number of Schedule I researchers registered to conduct research with marijuana and its extracts, concentrates and active compounds has increased from 161 in April 2014 to 344 in March 2016, an increase of more than 113 percent in two years.
Article
The DEA has already received the Food and Drug Administration's recommendation on the rescheduling, which is a key part of the rescheduling process stipulated by the Controlled Substance Act, says Russell Baer, a special agent at the DEA's office of public affairs. Baer won't reveal what the recommendation was. The DEA will now conduct its own eight-factor analysis to study the drug's potential for abuse, the current state of medical and scientific knowledge, the history and pattern of abuse, and other considerations. Once that is complete, the DEA's administrator, Chuck Rosenberg, makes the final call.
Baer wouldn't give a specific date for the decision, but he said the process is nearly complete and the agency is waiting to hear Rosenberg's decision whether or not marijuana is considered a medicine or if it's still a dangerous substance.
While the DEA continues to deliberate on whether or not to reschedule cannabis, the agency will continue to support increased medical and scientific studies on weed, says Baer.
According to the DEA, the total number of Schedule I researchers registered to conduct research with marijuana and its extracts, concentrates and active compounds has increased from 161 in April 2014 to 344 in March 2016, an increase of more than 113 percent in two years.